Liposomal Bupivacaine, Scientific Evidence, and the Clinician’s Conundrum

Editorial| May 2024 Liposomal Bupivacaine, Scientific Evidence, and the Clinician's Conundrum This article has an Audio Podcast James P. Rathmell, M.D. James P. Rathmell, M.D. 1Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. https://orcid.org/0000-0001-6780-9224 Search for other works by this author on: This Site PubMed Google Scholar Author and Article Information This editorial accompanies the article on p. 906. Accepted for publication January 29, 2024. Address correspondence to Dr. Rathmell: Anesthesiology May 2024, Vol. 140, 865–867. https://doi.org/10.1097/ALN.0000000000004935 Connected Content Article: Analgesic Effectiveness of Liposomal Bupivacaine versus Plain Local Anesthetics for Abdominal Fascial Plane Blocks: A Systematic Review and Meta-analysis of Randomized Trials Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Cite Icon Cite Get Permissions Search Site Citation James P. Rathmell; Liposomal Bupivacaine, Scientific Evidence, and the Clinician's Conundrum. Anesthesiology 2024; 140:865–867 doi: https://doi.org/10.1097/ALN.0000000000004935 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsAnesthesiology Search Advanced Search Topics: bupivacaine, liposomes It is New Year's Day 2024, and I am in my office in Boston on the first day in my new role as Editor-in-Chief of Anesthesiology. This morning, I decided to accept for publication a new systematic review and meta-analysis on liposomal bupivacaine for abdominal fascial plane blocks1 and three accompanying editorials solicited from an active clinical investigator,2 investigators of a randomized controlled trial of liposomal bupivacaine,3 and the chief medical officer and his colleagues at Pacira Biosciences, Inc. (Tampa, Florida), the company that manufactures and markets liposomal bupivacaine under the trademark Exparel.4 The purpose of this, my first editorial as editor-in-chief, is to provide readers of the Journal with my rationale for soliciting multiple opinions about this relatively simple study. To do so, it is helpful first to review the legal background of our having previously published similar papers in the Journal. On... You do not currently have access to this content.